GMP peptides explained: what GMP grade means, GLP vs GMP, and research grade vs GMP grade

“GMP peptide” is one of the most misused phrases in the peptide market. It is printed on research catalogues, quoted in tenders and asked about by laboratories that may never need it. In regulatory terms it has a specific meaning: the peptide was manufactured and released as an active pharmaceutical ingredient (API) under a good manufacturing practice quality system, which for APIs is set out internationally in ICH Q7. This guide explains what that involves, how GMP differs from GLP, how research grade, GMP grade and pharmacopoeial grade differ, and at which point in a research programme GMP material becomes necessary.

What is a GMP grade peptide?

A GMP grade peptide is a peptide made under good manufacturing practice for APIs. ICH Q7 states its objective as guidance on “good manufacturing practice (GMP) for the manufacturing of active pharmaceutical ingredients (APIs) under an appropriate system for managing quality”, to help ensure that APIs “meet the requirements for quality and purity that they purport or are represented to possess” [1]. In ICH Q7, “manufacturing” covers receipt of materials, production, packaging, labelling, quality control, release, storage and distribution [1].

The guideline was adopted at Step 4 on 10 November 2000 [1]. FDA publishes it as final guidance for industry, issued in its current form in September 2016 [2], and the EU adopted it first as Annex 18 and then as Part II of the EU GMP Guide [3]. The PIC/S GMP Guide reproduces it as its Part II, most recently in PE 009-18 dated 24 September 2026 [4]. FDA’s API inspection programme states that ICH Q7 “represents FDA’s current thinking on CGMP for APIs” and that facilities that follow it “will generally be considered in compliance with the statutory CGMP requirement” [5].

So “GMP grade” is not a purity number. A peptide can be 99% pure by HPLC and not be GMP; a GMP API can have a lower purity specification and still be GMP. GMP describes the system that produced and released the batch.

What GMP means for a peptide API under ICH Q7

ICH Q7 applies to APIs made “by chemical synthesis, extraction, cell culture/fermentation, by recovery from natural sources, or by any combination of these processes”, with specific guidance for cell culture and fermentation in section 18 [1]. Synthetic peptides made by solid phase or solution phase synthesis fall under the chemical manufacturing row of its Table 1; recombinant peptides fall under section 18.

Where GMP starts

GMP under ICH Q7 does not start at the first chemical in the plant. It starts at the “API starting material”, and the guideline “does not apply to steps prior to the introduction of the defined ‘API Starting Material’” [1]. The ICH Q7 Q&A adds that “an appropriate level of controls suitable for the production of the API starting material should be applied” even so, and that the starting material is normally defined in the regulatory filing [6]. ICH confirms that the ICH Q7 “API starting material” and the ICH Q11 “starting material” are the same material [7].

For synthetic peptides, EMA’s guideline (in effect from 1 June 2026) says that “protected natural L-amino acid derivatives (with terminal and side-chain protection as relevant) are generally acceptable as starting materials”, that short fragments such as certain dipeptides may be acceptable in justified cases, and that resins preloaded with the first amino acid are also starting materials while the unloaded resin is not [8]. In practice, GMP for an SPPS peptide therefore begins with the first coupling.

ICH Q7 stage (chemical manufacturing)	What it corresponds to in SPPS	GMP status	Ref
Production of the API starting material	Making protected amino acid derivatives	Outside ICH Q7, but appropriate controls expected	[1], [6]
Introduction of the starting material into the process	First use of protected amino acids or preloaded resin	GMP applies from here	[1], [8]
Production of intermediates	Chain assembly; cleavage and deprotection to crude peptide	GMP	[1], [8]
Isolation and purification	Preparative chromatography, pooling, salt exchange, lyophilisation	GMP, with increasing stringency	[1], [8]
Physical processing and packaging	Packing and labelling of the API	GMP	[1]

ICH Q7 states that “the stringency of GMP in API manufacturing should increase as the process proceeds from early API steps to final steps, purification, and packaging” [1]. For a peptide, the purification and isolation steps define the impurity profile, so this is where inspectors look hardest.

What a GMP system for a peptide API includes

ICH Q7 has 20 chapters (covered one by one in our ICH Q7 guide). The elements that most separate a GMP API from a research chemical are:

• An independent quality unit. “There should be a quality unit(s) that is independent of production and that fulfills both quality assurance (QA) and quality control (QC) responsibilities” [1].
• Records made at the time. “All quality related activities should be recorded at the time they are performed”, and deviations documented and explained [1].
• Annual product quality review of critical results, failed batches, deviations, changes, stability and complaints [1].
• Validation. Prospective process validation “should normally be performed for all API processes” and completed before commercial distribution of the drug product made from that API [1].
• Change control through a formal system that evaluates every change that may affect production and control [1].
• Certificates of Analysis issued “for each batch of intermediate or API on request”, listing each test, its acceptance limits and numerical results [1].
• Retention. Records kept for at least 1 year after expiry, or at least 3 years after complete distribution for APIs with retest dates; reserve samples kept on a similar basis [1].

Which GMP rules apply: ICH Q7, 21 CFR 210/211 and EU GMP Part II

Jurisdiction	Legal basis	GMP text for APIs	Note	Ref
United States	FD&C Act section 501(a)(2)(B): a drug not made under CGMP is adulterated	ICH Q7 as FDA guidance; inspections under compliance program 7356.002F	21 CFR Parts 210 and 211 set CGMP for finished drug products; Part 211 states its scope as “preparation of drug products”	[2], [9], [10], [5]
European Union	Directive 2001/83/EC Article 46(f): manufacturing authorisation holders must use only active substances made under GMP	EudraLex Volume 4, Part II	Part II began as Annex 18, “reflecting the EU’s agreement to ICH Q7A”	[3]
PIC/S participating authorities	National law	PIC/S GMP Guide Part II (PE 009-18)	Text “developed by the International Conference on Harmonisation”	[4]

Part 210 states that failure to comply with Parts 210 and 211 renders a drug adulterated under section 501(a)(2)(B) of the Act [9]. The FDA compliance program applies the same statutory requirement to API facilities, and covers “polypeptides consisting of up to 40 amino acids that are manufactured by chemical synthesis or fermentation” [5]. A synthetic peptide API sold for US drug manufacture is therefore inspected against ICH Q7, while the finished injectable made from it is held to Part 211.

GLP vs GMP: what is the difference?

GLP and GMP are often confused because both are “good practice” quality systems with independent quality assurance. They govern different activities.

The OECD defines GLP as “a quality system concerned with the organisational process and the conditions under which non-clinical health and environmental safety studies are planned, performed, monitored, recorded, archived and reported” [11]. In the US, 21 CFR Part 58 “prescribes good laboratory practices for conducting nonclinical laboratory studies that support or are intended to support applications for research or marketing permits” for FDA-regulated products [12].

	GLP	GMP (for APIs)
Governs	Nonclinical health and environmental safety studies	Manufacture, control, release, storage and distribution of APIs
Main texts	21 CFR Part 58 [12]; OECD Principles of GLP, revised 1997 [11]	ICH Q7 [1]; EU GMP Part II [3]; 21 CFR 210/211 for drug products [9], [10]
Unit of work	A study, under a study plan (protocol) and a Study Director	A batch, under master production instructions and a batch record
Independent oversight	Quality assurance unit “entirely separate from and independent of” study personnel [12]	Quality unit “independent of production” [1]
Key output	Final study report with a QA statement [11]	Released batch with Certificate of Analysis [1]
What it asks of the peptide	Characterisation of each batch of test article	That the peptide itself is made and released under GMP

Part 58 defines a nonclinical laboratory study as in vivo or in vitro experiments in which test articles are studied “to determine their safety”, and states that the term “does not include basic exploratory studies carried out to determine whether a test article has any potential utility” [12]. Mechanism, screening and early efficacy experiments in a research laboratory are therefore neither GLP nor GMP work.

What GLP asks of the test article

GLP asks for the test article to be characterised. Under 21 CFR 58.105, “the identity, strength, purity, and composition or other characteristics which will appropriately define the test or control article shall be determined for each batch and shall be documented”, methods of synthesis shall be documented, and stability shall be determined [12]. The OECD Principles say that for each study “the identity, including batch number, purity, composition, concentrations, or other characteristics to appropriately define each batch” should be known, its stability under storage and test conditions should be known, and a sample of each batch should be retained for all but short-term studies [11].

For a peptide going into a GLP toxicology study, that means a batch-specific analytical package (identity by mass spectrometry, HPLC purity and impurity profile, peptide content, counter-ion and water) and stability data. Whether the batch should also come from the intended clinical process is a development decision: impurities seen in toxicology are those against which later clinical batches are compared.

Research grade vs GMP grade vs pharmacopoeial grade peptides

None of the regulatory texts cited in this guide define “research grade” for a peptide. It is a supplier’s statement of intended use. US regulations prescribe the words “For Research Use Only” for in vitro diagnostic products “in the laboratory research phase of development”, which must carry the statement “For Research Use Only. Not for use in diagnostic procedures” [13]. For research chemicals, the label tells you what the material is not represented for; it does not tell you how it was made.

	Research grade (RUO)	GMP grade API	Pharmacopoeial grade
Meaning	Supplied for laboratory research; not for human or veterinary use	Manufactured and released under API GMP (ICH Q7 or EU Part II)	Complies with a Ph. Eur., USP or JP monograph
Who defines the standard	The supplier’s specification	ICH Q7 and national law [1], [3]	The pharmacopoeia
Typical intended use	In vitro work, analytical development, exploratory animal studies	Manufacture of medicines and investigational products	Medicines, where a monograph exists
Quality oversight	Depends on the supplier	Independent quality unit approves each batch [1]	Monograph tests; GMP is a separate question
Impurity thresholds	Set by the supplier	Justified in the dossier; in the EU, Ph. Eur. thresholds for peptide-related impurities: report above 0.1%, identify above 0.5%, qualify above 1.0% [8]	Set by the monograph
Regulatory file	None	US Type II DMF, EU ASMF, or applicant’s own dossier [14], [15]	A CEP is possible in the EU where a Ph. Eur. monograph exists [16]

The grades are not mutually exclusive. A GMP API can also comply with a monograph. But newer peptides often have no monograph, and the CEP procedure is “intended for substances for which a monograph, either general or specific, has been adopted by the European Pharmacopoeia Commission” [16]. For those peptides, the specification is justified in the dossier rather than taken from a pharmacopoeia.

What documentation each grade carries

Document	Research grade	GMP grade API	Basis
Batch Certificate of Analysis	Usually; content varies	Authentic CoA for each batch on request, listing each test, limits and numerical results, dated and signed by the quality unit	ICH Q7 11.4 [1]
Batch production record	Not normally available	Required; records of critical steps reviewed and approved by the quality unit before release	ICH Q7 6.5–6.7 [1]
Stability data and retest date	Sometimes	Retest or expiry date based on stability studies	ICH Q7 11.5–11.6 [1]
Change notification	Rarely	Changes evaluated under change control; drug product manufacturers notified of relevant changes	ICH Q7 13 [1]; Q7 Q&A [6]
Reserve samples	Supplier practice	Retained for a defined period after expiry or distribution	ICH Q7 11.7 [1]
Regulatory file	None	US DMF (not required by statute or regulation, and neither approved nor disapproved) or EU ASMF	FDA [14]; EMA [15]

The CoA alone is the weakest way to tell grades apart, because any supplier can produce one. Our guide to reading a peptide COA covers what a batch certificate should show; the GMP difference lies in the records, systems and regulatory file behind it.

When do researchers need GMP material?

The answer depends on what the peptide will be used for, not on how valuable the experiment is.

Use	GMP material needed?	What applies	Ref
In vitro assays, method development, exploratory animal studies	Not by regulation	Characterised material with a batch CoA; RUO is the normal grade	[12], [13]
GLP nonclinical safety studies	GLP governs the study; the test article must be characterised batch by batch	21 CFR 58.105; OECD GLP 6.2	[12], [11]
US phase 1 clinical supply	Statutory CGMP applies; Part 211 does not, until the drug is used in phase 2 or 3 or marketed	21 CFR 210.2(c); FDA phase 1 CGMP guidance; ICH Q7 section 19	[9], [17], [1]
US IND filing	Chemistry, manufacturing and control information for the drug substance	21 CFR 312.23(a)(7)	[18]
EU clinical trial supply	GMP for investigational medicinal products	Regulation (EU) No 536/2014, Delegated Regulation (EU) 2017/1569, Commission guidelines C(2017) 8179	[19]
EU IMPD	Quality documentation proportionate to phase; identity, impurities and assay mandatory	EMA IMPD guideline Rev. 2; EMA peptide guideline section 7	[20], [8]
Commercial medicine	Full API GMP, validated process, regulatory file	ICH Q7; EU Part II; DMF or ASMF	[1], [3], [14]

Clinical supply in the US

Under 21 CFR 210.2(c), “an investigational drug for use in a phase 1 study… is subject to the statutory requirements” of CGMP, but its production “is exempt from compliance with the regulations in part 211”; the exemption ends once the drug has been made available for a phase 2 or phase 3 study or lawfully marketed [9]. FDA’s phase 1 guidance adds that “manufacturers of new active pharmaceutical ingredients… must also conform with CGMP as required in § 501(a)(2)(B)” and “should implement CGMP appropriate to the stage of clinical development” [17].

The IND must contain “a section describing the composition, manufacture, and control of the drug substance”, and in an initial phase 1 submission the emphasis “should generally be placed on the identification and control of the raw materials and the new drug substance”; final specifications “are not expected until the end of the investigational process” [18].

ICH Q7 section 19: APIs for clinical trials

Section 19 accepts that “not all the controls in the previous sections of this Guide are appropriate for the manufacture of a new API for investigational use”, but requires “appropriate GMP concepts” with “a suitable mechanism of approval of each batch” and “a quality unit(s) independent from production” for the approval or rejection of each batch [1]. Process validation “is normally inappropriate, where a single API batch is produced”, while analytical methods that are not yet validated “should be scientifically sound” [1]. Labelling should “identify the material as being for investigational use” [1]. The ICH Q7 Q&A confirms that the same equipment can be used for preclinical and clinical material “as long as operations are conducted under GMP conditions” [6].

Clinical supply in the EU

EU good manufacturing practice for investigational medicinal products is set out in Commission Delegated Regulation (EU) 2017/1569 of 23 May 2017 and the Commission’s detailed guidelines of 8 December 2017, both based on Article 63(1) of Regulation (EU) No 536/2014 [19]. EMA’s IMPD guideline states that for the drug substance used in a trial “tests for identity, impurities and assay are mandatory”, with upper limits for impurities set with safety in mind [20].

EMA’s peptide guideline adds peptide-specific expectations for IMPs: individual impurities in amino acid building blocks should be monitored “from an early-stage”, with limits based on criticality assessment expected “for later development (phase II/III)”; peptide-related impurities “above the threshold of 1.0%, should be identified” and qualified in preclinical studies; and a prior-knowledge risk assessment of aggregation may be acceptable for phase I but should be “substantiated by experimental data” for phase II/III [8].

Can research use only peptides be used to make a clinical product?

The regulatory texts above describe the expectation: an investigational product’s active ingredient is manufactured under GMP appropriate to its phase, released by an independent quality unit, and described in the IND or IMPD with identity, impurity and assay data [1], [17], [20]. A research-use-only label means the supplier has not represented the material for that purpose. The practical route for a programme moving from research to the clinic is to source the API from a manufacturer that can supply GMP batches and the documentation the filing will reference, and to bridge the impurity profile from research batches to GMP batches analytically.

Questions to ask a supplier that says “GMP”

1. GMP to which standard, for which step? ICH Q7, EU Part II, or a national GMP? Does it cover API manufacture, or only a later step such as filling?
2. Which site? Name and address of each manufacturing and testing site, and its most recent regulatory inspection.
3. Where does GMP start? Which starting materials are declared, and why ([8], [7]).
4. Who releases the batch? An independent quality unit, and is the CoA signed by it ([1])?
5. Is there a regulatory file? A US DMF number, an EU ASMF, or a CEP, and will a letter of authorisation or access be provided ([14], [15])?
6. Will you be told about changes? Is there a quality agreement covering change notification and audits?

Our supplier qualification checklist covers each of these in depth, and the drug master file guide explains the regulatory files.

How Winhycare Pharma supplies peptides

Winhycare Pharma supplies research peptides as research-use-only material, at purity of ≥99% as stated in our product brochure, and offers custom peptide synthesis. Separately, semaglutide, tirzepatide, retatrutide, cagrilintide and BPC-157 are supplied as APIs to licensed manufacturers; see peptide APIs. For semaglutide we support US-DMF Type II dossiers and CTD Module 3 CMC documentation for customers’ own filings. Tell us whether your work is research or regulated manufacture and we will tell you which route and documents apply: request research peptides or enquire about semaglutide API.

For laboratory research use only. Not for human or veterinary use.